CLINICAL_TRIALS
trial_result
· 2018-02-07
Clinical Trial Update: Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera [Phase 2]
Summary
A Phase 2 trial of erlotinib in patients with JAK-2 V617F positive polycythemia vera has been terminated, with results posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Oklahoma | Conditions: Polycythemia Vera | Phase 2 | Status: TERMINATED | Results posted: 2018-02-07